{"id":"0e8c079a-e45e-52c3-b2db-57b16bd08fce","stable_key":"b26c9d01-98fd-50d3-8f39-44db46961ee5:acetate-weak-partial-agonism","predicate":"activates","statement":"Receptor studies confirmed acetate, propionate and butyrate to be low-potency partial agonists of FFAR2 compared with the synthetic agonist CFMB, which is a full agonist with roughly 750-fold higher potency than the short-chain fatty acids.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"b67f9872-3ee4-571f-a5a9-b86e147ee444","mechanism_event_label":"The natural fatty acids are weak at this receptor; a synthetic drug is hundreds of times stronger.","subject":{"id":"e366e758-1fb0-5573-aed1-34f6df874ac7","slug":"acetate","display_name":"Acetate","entity_type_key":"small_molecule"},"object":{"id":"2339ae63-1f30-58c0-8b4f-1a46c8a87418","slug":"ffar2","display_name":"Human free fatty acid receptor 2 / FFAR2","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"b67f9872-3ee4-571f-a5a9-b86e147ee444","stable_key":"b26c9d01-98fd-50d3-8f39-44db46961ee5:acetate-weak-partial-agonism-event","event_type":"biochemical_relationship","label":"The natural fatty acids are weak at this receptor; a synthetic drug is hundreds of times stronger.","description":"Receptor studies confirmed acetate, propionate and butyrate to be low-potency partial agonists of FFAR2 compared with the synthetic agonist CFMB, which is a full agonist with roughly 750-fold higher potency than the short-chain fatty acids.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"b77fa2f9-8a87-5565-95b9-d6e783880e85","slug":"cfmb-agonist","display_name":"CFMB / AR420626, a synthetic full agonist of FFAR2 and FFAR3","entity_type_key":"chemical_species"},"role":"reference_agonist","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"f3eec97e-b0aa-59a2-9947-b205a7efdb10","slug":"propionate","display_name":"Propionate","entity_type_key":"small_molecule"},"role":"co_tested_ligand","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"e7428a7f-d35a-5406-9904-a88984814833","slug":"butyrate","display_name":"Butyrate","entity_type_key":"small_molecule"},"role":"co_tested_ligand","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"e366e758-1fb0-5573-aed1-34f6df874ac7","slug":"acetate","display_name":"Acetate","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"2339ae63-1f30-58c0-8b4f-1a46c8a87418","slug":"ffar2","display_name":"Human free fatty acid receptor 2 / FFAR2","entity_type_key":"protein"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/acetate-research/29494208.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"9f8def7b832fdd5d5aed67891c84b18b597d558d9361a92412ccc44264b88126\", \"start_char\": 0, \"end_char\": 2445, \"text_sha256\": \"9f8def7b832fdd5d5aed67891c84b18b597d558d9361a92412ccc44264b88126\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Isolated perfused rat colon with luminal and vascular short-chain fatty acid infusion and receptor pharmacology","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Acetate, propionate and butyrate perfused luminally or vascularly, with FFAR2/FFAR3 agonists, an FFAR3 antagonist, nifedipine, diazoxide and 2,4-dinitrophenol","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"An isolated organ preparation with an intact blood supply. It reaches the opposite mechanistic conclusion from the knockout work in this collection and is why the receptor route is recorded as disputed.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Acetic acid research collection; topical membership is not evidence of a direct clinical effect, and the ingested acid is recorded separately from the circulating acetate anion.","comparator":null,"unit":null,"notes":"","entity":{"slug":"acetic-acid","display_name":"Acetic acid","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"Rat","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The natural fatty acids are weak at this receptor; a synthetic drug is hundreds of times stronger.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[acetate-p29494208] The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon. (2018). https://pubmed.ncbi.nlm.nih.gov/29494208/ DOI: 10.1152/ajpgi.00346.2017","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Colon","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"236e6587-e792-5d6b-80fc-936cced603d5","evidence_kind":"source_excerpt","locator":"Lines 355-366","start_line":355,"end_line":366,"excerpt":"### acetate-weak-partial-agonism\nReceptor studies confirmed acetate, propionate and butyrate to be low-potency partial agonists of FFAR2 compared with the synthetic agonist CFMB, which is a full agonist with roughly 750-fold higher potency than the short-chain fatty acids.\nCondition category: normal\nnutrient_topic: Acetic acid research collection; topical membership is not evidence of a direct clinical effect, and the ingested acid is recorded separately from the circulating acetate anion.\nplain_language: The natural fatty acids are weak at this receptor; a synthetic drug is hundreds of times stronger.\norganism: Rat\ntissue_or_cell_type: Colon\nexperimental_model: Isolated perfused rat colon with luminal and vascular short-chain fatty acid infusion and receptor pharmacology\nlimitations: An isolated organ preparation with an intact blood supply. It reaches the opposite mechanistic conclusion from the knockout work in this collection and is why the receptor route is recorded as disputed.\nexposure: Acetate, propionate and butyrate perfused luminally or vascularly, with FFAR2/FFAR3 agonists, an FFAR3 antagonist, nifedipine, diazoxide and 2,4-dinitrophenol\nevidence_span: {\"source_cache\": \"artifacts/acetate-research/29494208.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"9f8def7b832fdd5d5aed67891c84b18b597d558d9361a92412ccc44264b88126\", \"start_char\": 0, \"end_char\": 2445, \"text_sha256\": \"9f8def7b832fdd5d5aed67891c84b18b597d558d9361a92412ccc44264b88126\"}\n[acetate-p29494208] The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon. (2018). https://pubmed.ncbi.nlm.nih.gov/29494208/ DOI: 10.1152/ajpgi.00346.2017","model_system":"Isolated perfused rat colon with luminal and vascular short-chain fatty acid infusion and receptor pharmacology","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [acetate-p29494208] The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon. (2018). https://pubmed.ncbi.nlm.nih.gov/29494208/ DOI: 10.1152/ajpgi.00346.2017","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"8356baaf-173c-5549-80cd-bbbb2007ffb5","stable_key":"import-b26c9d01-98fd-50d3-8f39-44db46961ee5","title":"Acetic acid: the ingested acid, the receptors acetate binds, the acetyl-CoA it becomes, and the acetyl groups that reach histones (2026-09-21)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"1441d249b16db25c0d488407e5cc881222acffc2f16af88cb3197d9d5697bccc","revision_id":"9bfeb605-f589-5e99-84b9-e56968a3bc1f","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}